Según un informe denominado ‘El papel de los biosimilares en la salud’ elaborado por el Profesor Dr Claudio Tafla, médico especializado en urgencias y emergencias por la Universidad Pontificia Universidad Católica de São Paulo en Brasil, los medicamentos biológicos consumen alrededor del 40% del presupuesto público federal para la compra de medicamentos en asistencia farmacéutica en el Sistema Único de Salud (SUS), siendo la artritis reumatoide la responsable del mayor consumo de estos recursos [1].
- INICIO
-
Genéricos
Novedades
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Investigación
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
- Trajectories of prices in generic drug markets
-
Biosimilares
Novedades
- FDA approves Zymfentra and advances for Yuflyma in the US
- EC approval of natalizumab, aflibercept and tocilizumab biosimilars
- EMA recommends approval of first ustekinumab biosimilar Uzpruvo
- FDA approves first interchangeable ustekinumab biosimilar Wezlana
Investigación
- Biological therapies for psoriasis: evaluating durability and persistent benefits
- Switches between biosimilars and their reference products
- Latin America's biosimilars market: regulatory, institutional, and technological aspects
- Impact of trastuzumab biosimilars use in metastatic HER2-positive breast cancer
- MORE EDITORIAL SECTIONS
- Search
Post your comment